NutriBand Business Summary

NutriBand Inc. (NTRB) operates as a clinical-stage pharmaceutical company specializing in the development of transdermal drug delivery systems, primarily focused on its proprietary AVERSA™ abuse-deterrent technology. The company’s revenue model is currently transitioning from manufacturing-based sales—following the late 2025 agreement to divest a 90% stake in its Pocono Pharmaceutical subsidiary for $5 million—to a high-value intellectual property and licensing model centered on its lead candidate, AVERSA™ Fentanyl. This flagship product is designed to prevent opioid misuse through aversive agents, with a New Drug Application (NDA) filing targeted for 2026. NutriBand competes in the specialized transdermal and medical equipment markets against firms such as Kindeva Drug Delivery, Adhex Pharma, ProSolus, and Orchestra BioMed, positioning itself as a niche leader in the specific prevention of accidental exposure and intentional abuse of potent opioids. The company was co-founded by Gareth Sheridan and Serguei Melnik, who serve as CEO and Chairman/President, respectively. Sheridan is an award-winning entrepreneur who recently returned to the CEO role in October 2025 to lead the final development phase of AVERSA, while Melnik provides extensive expertise in capital markets and corporate strategy. The technical leadership is bolstered by COO Dr. Alan Smith, who also serves as President of the 4P Therapeutics subsidiary, and CSO Dr. Jeff Patrick, an expert in drug development from the Ohio State University Comprehensive Cancer Center. As of February 2026, the board has been expanded to include new directors Alessandro Puddu and Viorica Carlig to enhance governance. Notable institutional backing includes the Vanguard Group, which maintains a significant stake in the company as it approaches its 2026 clinical and regulatory milestones.